Brief: Nanobiotix Says New Preclinical Data Show Boosted Anti-Tumor Immune Activation

Nanobiotix SA

12/04/2022 08:43

April 12 (Reuters) - NANOBIOTIX  NANOB.PA :
    * ANNOUNCED ON MONDAY THAT NEW PRECLINICAL IMMUNOTHERAPY
DATA SHOW
BOOSTED ANTI-TUMOR IMMUNE ACTIVATION VIA TRIPLE BLOCKADE OF
PD-1, LAG-3, AND TIGIT WHEN COMBINED WITH RADIOTHERAPY-ACTIVATED
NBTXR3

   
 Source text for Eikon:  urn:newsml:reuters.com:*:nBw2BF0nQa
 Further company coverage:  NANOB.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))